Oxford BioTherapeutics

44 articles about Oxford BioTherapeutics

• Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024

  3/7/2024

  Oxford BioTherapeutics announces significant technological advances to its drug discovery platform OGAP® with a new version to be launched at the 14th Annual World ADC Conference in London named OGAP®-Verify.

• Oxford BioTherapeutics Announces First Patient Dosed with OBT076 in Phase 1b Trial in Adenoid Cystic Carcinomas of the Head and Neck

  1/18/2024

  Oxford BioTherapeutics announces that the first patient has been dosed in a Phase 1b trial investigating OBT’s lead candidate, OBT076, in patients with Adenoid Cystic Carcinoma of the head and neck.

• Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Potential Treatment of Advanced or Metastatic Large-Cell Neuroendocrine Carcinoma of the Lung

  11/29/2023

  Oxford BioTherapeutics today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BI 764532.

• Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764532 in Small Cell Lung Cancer and other Neuroendocrine Cancers

  10/24/2023

  Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, today announces that partner Boehringer Ingelheim dosed the first patient in a Phase 2 trial investigating BI 764532 (OBT620) for the treatment of small cell lung cancer (SCLC) and other neuroendocrine cancers.

• Oxford BioTherapeutics Relocates UK Headquarters to Strategic and Cutting-Edge R&D Location at The Oxford Science Park to Accelerate Development of its Immuno-Oncology and ADC-Based Cancer Therapies

  10/11/2023

  Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate -based therapies, announced that it has relocated its UK headquarters to The Schrodinger Building within The Oxford Science Park.

• Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers

  10/3/2023

  Oxford BioTherapeutics announces that the U.S. FDA has granted Fast Track designation to BI 764532 for the treatment of ES-SCLC whose disease has progressed following at least two prior lines of treatment including platinum-based chemotherapy, and of advanced or metastatic extrapulmonary neuroendocrine carcinomas whose disease has progressed following at least one prior line of treatment including platinum-based chemotherapy.

• Oxford BioTherapeutics to Participate in Panel Discussion at Boehringer Ingelheim’s Upcoming Transforming Science Day: Europe

  9/19/2023

  Oxford BioTherapeutics announces that its Chief Executive Officer, Christian Rohlff, will participate in the panel discussion titled “It takes a village: A holistic approach to external innovation” at Boehringer Ingelheim’s upcoming Transforming Science Day: Europe.

• Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumors by Dosing First Patient in Combination with CPI Balstilimab in Europe

  7/5/2023

  Oxford BioTherapeutics announced that it has initiated a Phase 1b combination trial evaluating its lead candidate, OBT076 - a CD205 targeting ADC - and Agenus’ proprietary anti-PD1 checkpoint inhibitor, balstilimab, in patients with advanced solid tumors by dosing its first patient at a European site.

• Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology

  5/25/2023

  Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate -based therapies, announced that it has extended its second multi-year collaboration with Boehringer Ingelheim for an additional two years.

• Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the head and neck

  4/19/2023

  Oxford BioTherapeutics Ltd. announces it has entered into a collaboration with Groupe d'Oncologie Radiothérapie Tête Et Cou to undertake a new Phase 1b trial investigating OBT’s lead asset, OBT076, in patients with Adenoid Cystic Carcinoma.

• Oxford BioTherapeutics to Announce New Fully Integrated ADC Engine at World ADC Conference 2023

  3/9/2023

  Oxford BioTherapeutics Ltd. announced it will reveal its new fully integrated ADC engine, combining its internationally recognised target discovery and ADC development capabilities, at the 13th Annual World ADC Conference being held in London, UK, from 13 to 16 March 2023.

• Oxford BioTherapeutics wins Tech Company of the Year and Special Recognition Award at Thames Valley SME Growth 100 Awards

  3/7/2023

  Oxford BioTherapeutics Ltd. announces it has been honoured with two prestigious awards: the ‘Tech Company of the Year’ and the ‘Special Recognition Award’, at The Business Magazine’s fourth annual Thames Valley SME Growth 100 Awards.

• 

  ADC Space Continues to Thrive with Four More Companies Linking Up

  6/16/2022

  This week sees Exelixis, BioInvent, ImmunoGen and Oxford BioTherapeutics coming together to develop antibody-based therapies for cancer.

• ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates

  6/13/2022

  ImmunoGen Inc. announced a multi-year collaboration to research novel, first-in-class ADCs with Oxford BioTherapeutics, a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, utilizing ImmunoGen's proprietary linker-payload technology directed to novel targets identified via OBT's proprietary OGAP® discovery platform.

• 

  Global Roundup: WuXi and Oxford BioTherapeutics Bolster Bispecific Program Deal

  1/21/2021

  Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.

• Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors

  1/6/2021

  Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. This pres

• Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

  10/14/2020

  The collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by Oxford BioTherapeutics’ proprietary OGAP ® (Oxford Genome Anatomy Project) target discovery platform, is the latest in a series of collaborations that strengthens Boehringer Ingelheim’s position and leading assets in cancer immunology. INGELHEIM, Germany & OXFORD, En

• 

  BioSpace Global Roundup, April 2

  4/2/2020

  Biopharma companies from across the globe provide updates on their pipelines and business practices.
• 

  WuXi Biologics and Oxford BioTherapeutics Expand Partnership With 5 More Antibody Compounds

  12/11/2018

  WuXi Biologics, a Shanghai, China-based contract research organization focused on biologics, announced it was expanding its existing collaboration and licensing deals with UK-based Oxford BioTherapeutics (OBT).

• Calculus Capital invests £2m in Oxford BioTherapeutics

  8/3/2018

  Calculus Capital, the award-winning Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) specialist, has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments.